KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Leases (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Current Leases for 6 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases fell 8.21% year-over-year to $12.7 million, compared with a TTM value of $12.7 million through Dec 2025, down 8.21%, and an annual FY2025 reading of $12.7 million, down 8.21% over the prior year.
  • Current Leases was $12.7 million for Q4 2025 at Recursion Pharmaceuticals, up from $11.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $13.8 million in Q4 2024 and bottomed at $499000.0 in Q1 2021.
  • Average Current Leases over 5 years is $6.6 million, with a median of $5.5 million recorded in 2022.
  • The sharpest move saw Current Leases surged 950.5% in 2022, then dropped 8.21% in 2025.
  • Year by year, Current Leases stood at $1.4 million in 2021, then soared by 320.34% to $6.0 million in 2022, then increased by 2.76% to $6.1 million in 2023, then skyrocketed by 125.56% to $13.8 million in 2024, then fell by 8.21% to $12.7 million in 2025.
  • Business Quant data shows Current Leases for RXRX at $12.7 million in Q4 2025, $11.5 million in Q3 2025, and $11.7 million in Q2 2025.